QUOTIENT THERAPEUTICS
LIVE

Serial Number

98015218

Owner

Flagship Labs 86, Inc.

Attorney

Christina M. Licursi

Filing Date

May 26, 2023

Add to watchlist:

No watchlists yet
View on USPTO

QUOTIENT THERAPEUTICS Trademark

Serial Number: 98015218

QUOTIENT THERAPEUTICS is a trademark filed by Flagship Labs 86, Inc. on May 26, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Flagship Labs 86, Inc. (2 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

QUOTIENT THERAPEUTICS, INC.

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

May 26, 2023

Registration Date

Not Registered

Published for Opposition

April 30, 2024

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Filing History

TEAS STATEMENT OF USE RECEIVED
Aug 3, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jun 25, 2026 EX4G
SOU EXTENSION 4 FILED
Jun 25, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 25, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 19, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 18, 2025 EX3G
SOU EXTENSION 3 FILED
Dec 18, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 18, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 19, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jun 18, 2025 EX2G
SOU EXTENSION 2 FILED
Jun 18, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 18, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 23, 2024 EX1G
SOU EXTENSION 1 FILED
Dec 23, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 23, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 25, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 21, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 26, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 30, 2023 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 6, 2023 NWOS